Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 60/771,251, filed Feb 8, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,422,367 | Antigenic GM-CSF Peptides and Antibodies to GM-CSF In force · High confidence | Eisai, Inc. | In force | High confidence | ||
| US 8,318,168 | Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf In force · High confidence | Eisai, Inc. | In force | High confidence | ||
| US 7,741,450 | Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf In force · High confidence | Eisai, Inc. | In force | High confidence | ||
| US 8,623,364 | Antigenic Gm-Csf Peptides and Antibodies to Gm-Csf Lapsed Jan 7, 2026 on the fee record Ended Jan 7, 2026 · High confidence | Eisai, Inc. | Lapsed Jan 7, 2026 on the fee record | Ended Jan 7, 2026 | High confidence | |
| US 10,023,632 | Antigenic GM-CSF Peptides and Antibodies to GM-CSF Lapsed Jul 17, 2026 on the fee record Ended Jul 17, 2026 · High confidence | Eisai, Inc. | Lapsed Jul 17, 2026 on the fee record | Ended Jul 17, 2026 | High confidence |
5 of 5 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Eisai Co., Ltd..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.